Mycobacterium ulcerans infection: control, diagnosis, and treatment.

[1]  A. Kolk,et al.  In Vitro Killing of Mycobacterium ulcerans by Acidified Nitrite , 2004, Antimicrobial Agents and Chemotherapy.

[2]  Kingsley Asiedu,et al.  Buruli Ulcer (M. ulcerans Infection): New Insights, New Hope for Disease Control , 2005, PLoS medicine.

[3]  C. Horsfield,et al.  Efficacy of the Combination Rifampin-Streptomycin in Preventing Growth of Mycobacterium ulcerans in Early Lesions of Buruli Ulcer in Humans , 2005, Antimicrobial Agents and Chemotherapy.

[4]  W. Secor,et al.  Buruli ulcer and schistosomiasis: no association found. , 2004, The American journal of tropical medicine and hygiene.

[5]  Hinrich W. H. Göhlmann,et al.  A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis , 2005, Science.

[6]  W. Meyers,et al.  Heat treatment of Mycobacterium ulcerans infections without surgical excision. , 1974, The American journal of tropical medicine and hygiene.

[7]  O. Adjei,et al.  Phenytoin in the treatment of Buruli ulcer. , 1998, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[8]  L. Marsollier,et al.  [Ecology and transmission of Mycobacterium ulcerans]. , 2003, Pathologie-biologie.

[9]  F. Portaels,et al.  Buruli ulcer disease in Cameroon rediscovered. , 2004, The American journal of tropical medicine and hygiene.

[10]  H. Fehr,et al.  Cotrimoxazol in the Treatment of Mycobacterium Ulcerans Infection (Buruli Ulcer) in West Africa , 1994, Tropical doctor.

[11]  Dhople Am.  Antimicrobial activities of dihydrofolate reductase inhibitors, used singly or in combination with dapsone, against Mycobacterium ulcerans , 2001 .

[12]  C. Zinsou,et al.  Distribution de l'infection à Mycobacterium ulcerans (Ulcère de Buruli) dans la commune de Lalo au Bénin , 2005 .

[13]  F. Portaels,et al.  Mycobacterium bovis BCG Vaccination as Prophylaxis against Mycobacterium ulcerans Osteomyelitis in Buruli Ulcer Disease , 2004, Infection and Immunity.

[14]  V. Jarlier,et al.  Activities of New Macrolides and Fluoroquinolones against Mycobacterium ulcerans Infection in Mice , 2001, Antimicrobial Agents and Chemotherapy.

[15]  J. Aubry,et al.  Écologie et mode de transmission de Mycobacterium ulcerans , 2003 .

[16]  P. Dijkstra,et al.  Distribution of Buruli ulcer lesions over body surface area in a large case series in Ghana: uncovering clues for mode of transmission. , 2005, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[17]  F. Portaels,et al.  Disseminated Mycobacterium ulcerans disease in an HIV-positive patient: a case study. , 2002, AIDS.

[18]  S. Cole,et al.  Isolation of Three Mycobacterium ulcerans Strains Resistant to Rifampin after Experimental Chemotherapy of Mice , 2003, Antimicrobial Agents and Chemotherapy.

[19]  R. Scherpbier,et al.  Buruli ulcer: Mycobacterium ulcerans infection. , 2000 .

[20]  D. Boakye,et al.  Potential Role for Fish in Transmission of Mycobacterium ulcerans Disease (Buruli Ulcer): an Environmental Study , 2004, Applied and Environmental Microbiology.

[21]  W. T. van der Graaf,et al.  Beliefs and attitudes toward Buruli ulcer in Ghana. , 2002, The American journal of tropical medicine and hygiene.

[22]  J. Kanga,et al.  [Contribution of heparin therapy in the medical treatment of Buruli ulcer apropos of 1 case]. , 2001, Bulletin de la Societe de pathologie exotique.

[23]  F. Portaels,et al.  Mycobacterium ulcerans Disease (Buruli Ulcer) in Rural Hospital, Southern Benin, 1997–2001 , 2004, Emerging infectious diseases.

[24]  L. Marsollier,et al.  Aquatic Insects as a Vector for Mycobacterium ulcerans , 2002, Applied and Environmental Microbiology.

[25]  S. Ostroff,et al.  Emergence of Buruli ulcer disease in the Daloa region of Cote d'Ivoire. , 1995, The American journal of tropical medicine and hygiene.

[26]  F. Portaels,et al.  Risk Factors for Buruli Ulcer, Benin , 2006, Emerging infectious diseases.

[27]  M. Wansbrough-Jones,et al.  An outreach education and treatment project in Ghana for the early stage of Mycobacterium ulcerans disease. , 2003, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[28]  K. Asiedu,et al.  Buruli Ulcer in Ghana: Results of a National Case Search , 2002, Emerging infectious diseases.

[29]  R. Spiegel,et al.  A pilot study of treatment of Buruli ulcer with rifampin and dapsone. , 2002, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[30]  F. Portaels,et al.  Mycobacterium ulcerans disease. , 2005, Bulletin of the World Health Organization.

[31]  A. M. Dhople,et al.  In vitro activity of sitafloxacin (DU-6859a) alone, or in combination with rifampicin, against Mycobacterium ulcerans. , 2002, The Journal of antimicrobial chemotherapy.

[32]  S. Djakeaux,et al.  [Therapeutic approach in Mycobacterium ulcerans infections]. , 1994, Bulletin de la Societe de pathologie exotique.

[33]  Samuel Asamoah,et al.  Effectiveness of Excision of Pre-Ulcerative Buruli Lesions in Field Situations in a Rural District in Ghana , 1998, Tropical doctor.

[34]  F. Portaels,et al.  [Distribution of Mycobacterium ulcerans (Buruli ulcer) in the district of Lalo in Benin]. , 2005, Tropical medicine & international health : TM & IH.

[35]  Christina Drummond,et al.  Mycobacterium ulcerans Treatment Costs, Australia , 2004, Emerging infectious diseases.

[36]  J. T. Scott,et al.  Mycobacterium ulcerans disease: role of age and gender in incidence and morbidity , 2004, Tropical medicine & international health : TM & IH.

[37]  S. Guadagnini,et al.  Colonization of the salivary glands of Naucoris cimicoides by Mycobacterium ulcerans requires host plasmatocytes and a macrolide toxin, mycolactone , 2005, Cellular microbiology.

[38]  M. Wansbrough-Jones,et al.  Buruli ulcer. , 2000, Current opinion in infectious diseases.

[39]  F. Portaels,et al.  Psychosocial aspects of health seeking behaviours of patients with Buruli ulcer in southern Benin , 2003, Tropical medicine & international health : TM & IH.

[40]  P. Smith,et al.  The protective effect of BCG against Mycobacterium ulcerans disease: a controlled trial in an endemic area of Uganda. , 1976, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[41]  N. Honoré,et al.  Susceptibility of Mycobacterium ulcerans to a combination of amikacin/rifampicin. , 2003, International journal of antimicrobial agents.

[42]  V. Jarlier,et al.  Activities of Several Antimicrobials againstMycobacterium ulcerans Infection in Mice , 2000, Antimicrobial Agents and Chemotherapy.

[43]  J. Guarner,et al.  Immunoglobulin M Antibody Responses to Mycobacterium ulcerans Allow Discrimination between Cases of Active Buruli Ulcer Disease and Matched Family Controls in Areas Where the Disease Is Endemic , 2004, Clinical Diagnostic Laboratory Immunology.

[44]  J. Hayman,et al.  A large localized outbreak of Mycobacterium ulcerans infection on a temperate southern Australian island , 1997, Epidemiology and Infection.

[45]  J. Kanga,et al.  [Epidemiologicl aspects of Buruli ulcer in Côte d'Ivoire: results of a national survey]. , 2001, Bulletin de la Societe de pathologie exotique.

[46]  A. M. Dhople,et al.  Activities of Sitafloxacin (DU-6859a), Either Singly or in Combination with Rifampin, Against Mycobacterium ulcerans Infection in Mice , 2003, Journal of chemotherapy.

[47]  M. Debacker,et al.  Buruli Ulcer Recurrence, Benin , 2005, Emerging infectious diseases.

[48]  Caroline Deshayes,et al.  Mycobacterium pseudoshottsii sp. nov., a slowly growing chromogenic species isolated from Chesapeake Bay striped bass (Morone saxatilis). , 2005, International journal of systematic and evolutionary microbiology.

[49]  F. Portaels,et al.  Protective Efficacy of a DNA Vaccine Encoding Antigen 85A from Mycobacterium bovis BCG against Buruli Ulcer , 2001, Infection and Immunity.

[50]  J. Tappero,et al.  Mycobacterium ulcerans infection , 1999, The Lancet.

[51]  M. Goto,et al.  [Comparison of inhibitory effect of rifalazil and rifampicin against Mycobacterium ulcerans infection induced in mice]. , 2004, Kekkaku : [Tuberculosis].

[52]  F. Portaels,et al.  Buruli ulcer (Mycobacterium ulcerans infection). , 2008, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[53]  V. Jarlier,et al.  Bactericidal Activity of Rifampin-Amikacin against Mycobacterium ulcerans in Mice , 2002, Antimicrobial Agents and Chemotherapy.

[54]  J. Guarner,et al.  Risk factors for Buruli ulcer disease (Mycobacterium ulcerans Infection): results from a case-control study in Ghana. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[55]  T. Grammer,et al.  A Newly Discovered Mycobacterial Pathogen Isolated from Laboratory Colonies of Xenopus Species with Lethal Infections Produces a Novel Form of Mycolactone, the Mycobacterium ulcerans Macrolide Toxin , 2005, Infection and Immunity.

[56]  L. Parrot,et al.  Bull. Soc. Path. Exot. , 1920 .

[57]  F. Portaels,et al.  In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans. , 2000, The Journal of antimicrobial chemotherapy.

[58]  P. Rácz,et al.  Dry-Reagent-Based PCR as a Novel Tool for Laboratory Confirmation of Clinically Diagnosed Mycobacterium ulcerans-Associated Disease in Areas in the Tropics Where M. ulcerans Is Endemic , 2005, Journal of Clinical Microbiology.

[59]  K. Huygen.  Prospects for vaccine development against Buruli disease , 2003, Expert review of vaccines.

[60]  F. Portaels,et al.  Schistosoma haematobium Infection and Buruli Ulcer , 2004, Emerging infectious diseases.

[61]  M. Pike,et al.  A controlled trial of the treatment of Mycobacterium ulcerans infection with clofazimine. , 1973, Lancet.

[62]  R. Phillips,et al.  Pilot Randomized Double-Blind Trial of Treatment of Mycobacterium ulcerans Disease (Buruli Ulcer) with Topical Nitrogen Oxides , 2004, Antimicrobial Agents and Chemotherapy.

[63]  M. Sarkar,et al.  Buruli ulcer: a systemic disease. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[64]  F. Portaels,et al.  Genotyping Mycobacterium ulcerans and Mycobacterium marinum by Using Mycobacterial Interspersed Repetitive Units , 2005, Journal of bacteriology.

[65]  A. M. Dhople,et al.  Antimicrobial activities of dihydrofolate reductase inhibitors, used singly or in combination with dapsone, against Mycobacterium ulcerans. , 2001, The Journal of antimicrobial chemotherapy.